Our initial article on LymPro back in April 2013 outlined our belief that the diagnostic division at Amarantus, which includes earlier-stage product, NuroPro for the diagnosis of Parkinson's disease, is worth $50 million in value. We think MANF is worth $40 million in value, as outlined in our initiation report from May 2013. Thus, we think Amarantus is worth $90 million today, and that represents over 200% upside from today - or a target price of $0.20 per share.
Friday's C.E.O.'s Blog: Up Listing to national exchange and no additional funding required.
Read the recent Yahoo news.
If you've ever considered investing in a micro cap biotech "AMBS" is the one to invest in on Monday.
Buy a few shares and hold them for six months.
Twitter: @AmarantusBio .... 8,530 followers
Yellen isn't going to risk tanking the economy. Obama's approval rating is at an all time low.
"AMBS" - Buy a few shares under a nickle and hold them for six months.
Jason Napadano says it's currently a "BUY" and is worth .20.
Follow the company on Twitter: @AmarantusBio
If so then go buy a few shares of "AMBS" and hold them for a year. Zack's bio-tech analyst, Jason Napadano, recently placed a "BUY" rating on the stock with a .20 price target. One of the few times he's ever recommended buying a penny stock. Read the recent Yahoo news.
Deal with Becton Dickinson is in the works.
Follow the company on Twitter: @AmarantusBio .... 8,587 followers
AMBS - Most undervalued bio-tech in the market. Read the recent Yahoo news.
Expected to announce a deal soon with Becton Dickinson for its diagnostic test to detect early stage Alzheimer's. Potential $500,000,000 annual market.
Company's patented drug, MANF, could be the blockbuster drug of the 21st century. Due diligence.
Current market cap: $29M
Under a dime a share currently.
Follow the company on Twitter: @AmarantusBio .... 8,542 followers
China will be the new Hunt Brothers as it corners the market on gold. It's goal is to make China's currency the global standard replacing the U.S. dollars. Gold could triple in price in the next three years.
The Chinese are long term planners. Their time frame is longer than the next reporting period.
"AMBS" - Becton Dickinson confirms validity for the company's diagnostic test to detect early stage Alzheimer's. Commercial launch in the second half of 2014.
Potential $500,000,000 annual market in the U.S.
Read today's Yahoo news.